CSIMarket
 


T2 Biosystems Inc   (TTOO)
Other Ticker:  
 
 

TTOO's Net Cash Flow Growth by Quarter and Year

T2 Biosystems Inc 's Net Cash Flow results by quarter and year




TTOO Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -9.62 0.20 -2.27
III Quarter September 8.24 7.15 -9.66 -7.10
II Quarter June 5.97 3.82 22.02 -9.79
I Quarter March -1.21 -13.27 -6.10 25.29
FY   13.00 -11.92 6.46 6.13



TTOO Net Cash Flow third quarter 2023 Y/Y Growth Comment
T2 Biosystems Inc achieved in the third quarter 2023, above Company average Net Cash Flow increase of 15.17% year on year, to $ 8.24 millions.

Looking into third quarter 2023 results within Medical Equipment & Supplies industry 29 other companies have achieved higher Net Cash Flow growth. While T2 Biosystems Inc ' s Net Cash Flow growth of 15.17% ranks overall at the positon no. 527 in the third quarter 2023.




TTOO Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September 15.17 % - - -
II Quarter June 56.28 % -82.65 % - -
I Quarter March - - - -
FY   - - 5.38 % -

Financial Statements
T2 Biosystems Inc 's third quarter 2023 Net Cash Flow $ 8.24 millions TTOO's Income Statement
T2 Biosystems Inc 's third quarter 2022 Net Cash Flow $ 7.15 millions Quarterly TTOO's Income Statement
New: More TTOO's historic Net Cash Flow Growth >>


TTOO Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September 37.94 % 87.17 % - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - 5.38 % -




Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #30
Healthcare Sector #89
Overall #527

Net Cash Flow Y/Y Growth Statistics
High Average Low
56.41 % -36.8 % -100 %
(Jun 30 2023)   (Sep 30 2018)
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #30
Healthcare Sector #89
Overall #527
Net Cash Flow Y/Y Growth Statistics
High Average Low
56.41 % -36.8 % -100 %
(Jun 30 2023)   (Sep 30 2018)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

T2 Biosystems Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
87.52 % 62.77 % 38.01 %
(Sep 30 2022)  


TTOO's III. Quarter Q/Q Net Cash Flow Comment
T2 Biosystems Inc achieved in the III. Quarter 2023 below company average Net Cash Flow jump of 37.94% quarter on quarter, to $ 8.24 millions.

Within Medical Equipment & Supplies industry 23 other companies have achieved higher Net Cash Flow quarter on quarter growth. While T2 Biosystems Inc 's Net Cash Flow growth quarter on quarter, overall rank is 399.


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #69
Overall #399
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #69
Overall #399
Net Cash Flow Q/Q Growth Statistics
High Average Low
87.52 % 62.77 % 38.01 %
(Sep 30 2022)  


TTOO's III. Quarter Q/Q Net Cash Flow Comment
T2 Biosystems Inc achieved in the III. Quarter 2023 below company average Net Cash Flow jump of 37.94% quarter on quarter, to $ 8.24 millions.

Within Medical Equipment & Supplies industry 23 other companies have achieved higher Net Cash Flow quarter on quarter growth. While T2 Biosystems Inc 's Net Cash Flow growth quarter on quarter, overall rank is 399.


T2 Biosystems Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ 3.37 $ 2.29 $ 0.14 $ -11.92 $ -2.10
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) 47.16 % 1537.14 % - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 38 # 45 # 247 # 0 # 439




Cumulative Net Cash Flow growth Comment
T2 Biosystems Inc saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 15.17% year on year, to $ 3 millions if the fiscal year would have ended in Sep 30 2023.
T2 Biosystems Inc 's trailing twelve months Net Cash Flow growth was higher than company's average 0% and higher than % growth in Jun 30 2023. And, T2 Biosystems Inc realized the fastest Net Cash Flow growth, in Medical Equipment & Supplies industry. In the Sep 30 2023 period, T2 Biosystems Inc had cumulative twelve months Net Cash Flow of $ 3 millions compare to net cash outflow of $ -2 millions a year ago.
Even more so, not just that Medical Equipment & Supplies company has regained the bottom-line, T2 Biosystems Inc is, as of now gaining momentum with higher than usual Net Cash Flow surge, from the twelve months ending in the quarter before of 47.16 % from $2.29 millions.

T2 Biosystems Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
5.24 %
-196.88 %
-388.79 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 6
S&P 500 # 38
Cumulative Net Cash Flow growth Comment
T2 Biosystems Inc saw improvement in Net Cash Flow growth trend, posting cumulative 12 months Net Cash Flow growth of 15.17% year on year, to $ 3 millions if the fiscal year would have ended in Sep 30 2023.
T2 Biosystems Inc 's trailing twelve months Net Cash Flow growth was higher than company's average 0% and higher than % growth in Jun 30 2023. And, T2 Biosystems Inc realized the fastest Net Cash Flow growth, in Medical Equipment & Supplies industry.
The progress was much more impressive from the previous reporting period showed at 47.16 % rise from $2.29 millions in the period from Jun 30 2023 to Sep 30 2022. In the Sep 30 2023 period, T2 Biosystems Inc had cumulative twelve months Net Cash Flow of $ 3 millions compare to net cash outflow of $ -2 millions a year ago.
Even more so, not just that TTOO has returned to prosperity, the company is already gaining momentum and showing above average Net Cash Flow gain, from the twelve months ending in the quarter before of 47.16 % from $2.29 millions.

T2 Biosystems Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
5.24 %
-196.88 %
-388.79 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 6
S&P 500 # 38




Other Net Cash Flow Growth
Medical Equipment & Supplies Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
TTOO's Net Cash Flow Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for TTOO's Competitors
Net Cash Flow Growth for T2 Biosystems Inc 's Suppliers
Net Cash Flow Growth for TTOO's Customers

You may also want to know
TTOO's Annual Growth Rates TTOO's Profitability Ratios TTOO's Asset Turnover Ratio TTOO's Dividend Growth
TTOO's Roe TTOO's Valuation Ratios TTOO's Financial Strength Ratios TTOO's Dividend Payout Ratio
TTOO's Roa TTOO's Inventory Turnover Ratio TTOO's Growth Rates TTOO's Dividend Comparisons



Companies with similar Net Cash Flow jump for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Amicus Therapeutics inc 24.64%$ 24.638 millions
Stryker Corp22.07%$ 22.074 millions
Mersana Therapeutics Inc 18.07%$ 18.068 millions
Pacific Biosciences Of California Inc 15.91%$ 15.913 millions
Davita Inc 15.48%$ 15.476 millions
T2 Biosystems Inc 15.11%$ 15.110 millions
Harvard Bioscience Inc14.80%$ 14.802 millions
Revance Therapeutics Inc 8.58%$ 8.585 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com